The European Commission announced today that it has entered into a contract with Novavax to pre-purchase 200 million doses of vaccine against it coronavirus, once approved by the European Medicines Agency (EMA).
“Our new agreement with Novavax expands our vaccine portfolio by adding another vaccine“, based on protein, a platform that looks promising in clinical trials”, said the Health Commissioner Stella Kyriakidou.
ΑΠΕ ΜΠΕ talks about seventh contract concluded by the Commission with a pharmaceutical company to secure access to a possible COVID-19 vaccine. In particular, under this agreement, EU Member States will be able to purchase up to 100 million doses of the US company vaccine, with a choice of an additional 100 million doses during 2021, 2022 and 2023, after being reviewed and approved by the EMA as safe and effective.
The current contract complements the extensive vaccine portfolio developed by the European Commission, including contracts with the AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, Modern and comprehensive exploratory talks with Valneva.
The President of the European Commission, Ursula von der Leyen“As new coronavirus variants spread across Europe and around the world, this new contract with a company that is already successfully testing its vaccine against these variants is an additional guarantee for the protection of our population. “It further strengthens the broad portfolio of vaccines, for the benefit of Europeans and our partners worldwide.”
According to the Commission announcement, Novavax is a biotechnology company developing vaccines next generation for serious infectious diseases. Its COVID-19 vaccine is already under rolling evaluation by the EMA, with a view to a possible marketing authorization. The Commission decided to support this vaccine on the basis of a sound scientific evaluation, the technology used, the company’s experience in vaccine development and its production capacity.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.